Astria Therapeutics — Catabasis Pharmaceuticals — Merger or Acquisition (January 2021)
21 slides from Astria Therapeutics's merger presentation, Jan 29, 2021
Slide 1: Investor Presentation January 2021
Investor Presentation January 2021
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and various remarks we make during this presentation contain forward - looking statements of Catabasis Pharmaceuticals, Inc . (“Catabasis,” the “Company,” “we”, “our” or “us”) within the meaning of the Private Securities Litigation Reform Act of 1995 , in
Slide 3: Overview
Overview 3 Our Mission T o bring hope with life - changing therapies to patients and families affected by rare diseases Our Approach Engineered a differentiated high affinity, long plasma half - life, humanized monoclonal antibody inhibitor of plasma kallikrein Our Lead Asset QLS - 215, a potential
Slide 4: Catabasis Acquisition of Quellis
Catabasis Acquisition of Quellis 4 Transaction Summary Premier Investors and Alignment of Interest Use of Proceeds Key Management and Board • Catabasis Pharmaceuticals, Inc. (“Catabasis,” Nasdaq: CATB) has acquired Quellis Biosciences, Inc . (“Quellis”) − Quellis is a preclinical virtual biotech com
Slide 5: Hereditary Angioedema: A Rare, Potentially Life-Threatening Disease
Hereditary Angioedema: A Rare, Potentially Life - Threatening Disease 5 1. Busse PJ, et al. J Allergy Clin Immunol Pract 2021; 9(1):132 - 150.e3. 2. Zuraw BL. Hereditary angioedema. N Engl J Med. 2008;359:1027 - 36. 3. Lumry WR. Front. Med., 16 Feb 2019. doi:10.3389/fmed.2018.00022. 4. Bork K, et al
Slide 6: High Patient Burden: HAE Attacks are Unpredictable, Debilitating and Potentially Life-Threatening
High Patient Burden: HAE Attacks are Unpredictable, Debilitating and Potentially Life - Threatening Common triggers include: - Physical activity with repeated pressure, excessive exposure to sun, cold, water - Illness, emotional stress, hormonal fluctuations - Medical/dental work - Certain medicatio
Slide 7: Dysregulation of the Plasma Contact System Mediates Excessive Swelling Underlying HAE Symptoms
Dysregulation of the Plasma Contact System Mediates Excessive Swelling Underlying HAE Symptoms 7 Factor XIIa pKal Activated Factor XII ( FXIIa ) produces pKal plasma kallikrein (pKal) cleaves HMWK to produce Bradykinin Bradykinin binds to receptors on endothelial cells, fluid leakage into tissues Tr
Slide 8: Treatment Landscape Has Advanced but Unmet Need Remains
Treatment Landscape Has Advanced but Unmet Need Remains 8 1 Fortune Business Insights, Healthcare/Hereditary Angioedema Treatment Market, Report ID: FBI100165. Acute treatments to limit severity and duration of attacks as they occur Prophylactic treatments to prevent attacks Unmet need for prophylax
Slide 9: TAKHZYRO Studies Have Established Plasma Kallikrein mAb as an Important Therapy for HAE
TAKHZYRO ® (lanadelumab - flyo ) Injection Studies Have Established Plasma Kallikrein mAb as an Important Therapy for HAE 9 Banerji, A., M.A. Riedl, et al. (2018) Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial. JAMA 320(20):210
Slide 10: mAb: Opportunity for Best-in-Class Agent
QLS - 215 mAb: Opportunity for Best - in - Class Agent 10 QLS - 215 Goals Potential Benefits High potency for pKal • Long duration without breakthrough attacks • Small injection volume Extended plasma half - life • Infrequent dosing • Long duration without breakthrough attacks Clinical proof of conc
Slide 11: Designed from Inception to be Potentially a Best-in-Class Prophylactic Therapy
QLS - 215 Designed from Inception to be Potentially a Best - in - Class Prophylactic Therapy for Patients Affected by HAE 11 >11,000 hybridomas 3840 pKal binders ~20 hits selective for pKal vs. pre - Kal 1 hit selective and inhibitory Humanized Optimized QLS - 215 Humanized monoclonal antibody havin
Slide 12: In an in vitro Functional Assay QLS-215 Was More Potent than Lanadelumab
In an in vitro Functional Assay QLS - 215 Was More Potent than Lanadelumab in Inhibiting Bradykinin Production 12 pKal levels 30 - 110nM estimated in HAE plasma (Kenniston et al JBC 2014) Lanadelumab QLS - 215 pKal IC 90 (nM) 300 30 • IC 90 determined by bradykinin ELISA to detect cleavage of high m
Slide 13: QLS-215 Has Shown Substantially Prolonged Plasma Half-Life Compared to Lanadelumab in Non-Human Primates
QLS - 215 Has Shown Substantially Prolonged Plasma Half - Life Compared to Lanadelumab in Non - Human Primates 13 Data from concurrent but independent experiments in cynomolgus monkeys Lanadelumab data are representative of 3 independent experiments that all showed t 1/2 ~10 days • FDA review docume
Slide 14: In vitro Potency and NHP PK Data Predict a Substantially Longer Duration of Action
The in vitro Potency and NHP PK Data for QLS - 215 Predict a Substantially Longer Duration of Action than Lanadelumab 14 IC 90 from cleavage of 600 nM HMWK with 30 nM pKal • Lanadelumab plasma levels fall below predicted minimum therapeutic concentration (IC90) by approximately day 10 • QLS - 215 re
Slide 15: PK/PD Model from Preclinical Studies Predicts Longer Duration of Action
PK/PD Model from Preclinical Studies Predicts Longer Duration of Action for QLS - 215 15 pKal levels 30 - 110nM reported in HAE plasma (Kenniston et al JBC 2014) 0 20 40 60 80 100 0 50 100 NHP PK, 5 mg/kg Time (Days) % p K a l i n h i b i t i o n QLS-215 DX2930 • Model based on plasma concentrations
Slide 16: mAb Developed with the Desired Characteristics
QLS - 215 mAb Developed with the Desired Characteristics 16 QLS - 215 Goals Status High potency for pKal Extended plasma half - life in NHP Clinical proof of concept New therapy for HAE prophylaxis Goal: Make the best possible pKal antibody to treat HAE with infrequent dosing and sustained blood lev
Slide 17: Opportunity for Proof of Concept in Early Clinical Trials
Opportunity for Proof of Concept in Early Clinical Trials Phase 1a Clinical Trial Design • Subjects: Adult healthy volunteers • Objectives: assess safety and PK • Single escalating doses Goals • Demonstrate safety and prolonged half - life as proof of concept in humans • Determine activity with an e
Slide 18: Estimated Timeline and Cash
Estimated Timeline and Cash • Cash, cash equivalents and short - term investments following closing of transactions will be approximately $150M • Expected cash runway through 2023 18 2021 2022 2023 QLS - 215 • Conduct IND - enabling activities • Initiate GMP manufacture • Develop Phase 1a trial desi
Slide 19: Opportunity
QLS - 215 Opportunity 19 Treatment for rare, genetic disease with established clinical and regulatory path Targeting a clinically validated mechanism with a trusted modality Potential for best - in - class agent that provides greater efficacy and ease of use Candidate with differentiated preclinical
Slide 20: Vision for Catabasis
Vision for Catabasis 20 Value Time Today • Acquisition of Quellis • Advance QLS - 215 to IND - IND - enabling activities - GMP manufacture - Phase 1a design Tomorrow • Establish clinical PoC • Advance 2nd program Future • Submit QLS - 215 BLA • Expand rare disease pipeline
Slide 21: catabasis.com
I\ catabasis catabasis.com
Catabasis Pharmaceuticals — Merger or Acquisition (January 2021) on 6ix